Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE ROLE OF S-AMLODIPINE IN ARTERIAL HYPERTENSION THERAPY WITH COMBINATION OF CALCIUM CHANNEL BLOCKERS AND BETA-BLOCKERS

https://doi.org/10.20996/1819-6446-2013-9-3-236-240

Full Text:

Abstract

Aim. To study efficacy and safety of calcium channel blocker, S-amlodipine, in combination with β-blocker, atenolol, in patients with arterial hypertension (HT) 1-2 degree com- pared to fixed combination of racemic amlodipine and atenolol.
Material and methods. Patients (n=31, 7 men and 24 women) with HT 1–2 degree were included into the study. The patients were randomized into two groups by the com- binations sequence. Treatment with each combination lasted 4 weeks. Office blood pressure (BP) was assessed at baseline and at the end of the treatment periods, possible side effects were registered.
Results. All patients completed the study. Both combination of S-amlodipine+atenolol and fixed combination of racemic amlodipine+atenolol reduced systolic (in average, -15.9 and -12.7 mm Hg, respectively) and diastolic (in average, -7.3 and -5.3 mmHg, respectively) BP significantly. Heart rate also decreased during therapy (in average, -3 and -4 bt/min, respectively). The differences between combinations BP and heart rate effects were not significant. 8 and 16 adverse events were registered during S-amlodipine+atenolol and racemic amlodipine+atenolol therapies, respectively Conclusion. Combination of S-amlodipine+atenolol, as well as combination of racemic amlodipine+atenolol are effective in the treatment of patients with HT 1-2 degree, however combination with S-amlodipine has less number of adverse events.

About the Authors

M. A. Maksimova
State Research Center for Preventive Medicine, Moscow
Russian Federation


Yu. V. Lukina
State Research Center for Preventive Medicine, Moscow
Russian Federation


S. Yu. Martsevich
State Research Center for Preventive Medicine, I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation


References

1. Feldsherova NA, Semernin EN. Amlodipine: a review of clinical studies. Good Clinical Practice 2002; (2): 27–33. Russian (Фельдшерова, Н.А., Семернин Е.Н. Амлодипин: обзор клинических исследований. Качественная Клиническая Практика 2002;(2):27–33).

2. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients random- ized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981–97.

3. Dahlöf B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.

4. Julius S., Kjeldsen S.E., Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–31.

5. Burges R.A., Gardiner D.G., Gwilt M. et al. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receceptors. J. Cardiovasc Pharmacol 1987; 9:110–9.

6. Lekha Pathak, Hiremath M.S., Manade V.G., Kerkar P.G. Multicentric, Clinical Trial of S-Amlodipine 2.5 mg Versus Amlodipine 5 mg in the Treatment of Mild to Moderate Hypertension – A Randomized, Dou- bleblind Clinical Trial. JAPI 2004; 52: 197–202.

7. Kerkar P.G. Clinical Trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the Treatment of Hyper- tension. Indian Journal of Clinical Practice 2003; 13(11):49–53.

8. SESA study. Safety and efficacy of S(-)Amlodipine. JAMA India 2003; 2(8):87–92.

9. Maximova MA, Lukina YV, Tolpygina SN et al. A comparative study of the efficacy and safety of a new drug S-amlodipine in hypertensive patients with grade 1–2. Rational Pharmacother Card 2008, 2 (4): 34–7. Максимова М.А., Лукина Ю.В., Толпыгина С.Н. и др. Сравнительное изучение эффективности и безопасности нового препарата S-амлодипина у больных артериальной гипертонией 1–2 степени. РФК 2008; 2(4): 34–7.

10. Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Systemic Hypertension 2010; (3): 1–34. Russian (Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные Гипертензии 2010; (3): 1–34).

11. Thacker H.P. (2007) S-amlodipine – The 2007 Clinical Review. J Indian Med Assoc 1005:180–90.


For citation:


Maksimova M.A., Lukina Y.V., Martsevich S.Y. THE ROLE OF S-AMLODIPINE IN ARTERIAL HYPERTENSION THERAPY WITH COMBINATION OF CALCIUM CHANNEL BLOCKERS AND BETA-BLOCKERS. Rational Pharmacotherapy in Cardiology. 2013;9(3):236-240. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-3-236-240

Views: 705


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)